PerioChip®

A biodegradable periodontal chip releasing 2.5mg Chlorhexidine Gluconate over a period of 10 days

View Dexcel's vision
Novel OTC formulation

Novel Formulation of a well-known US OTC Brand

Omeprazole DR Tablets

Proprietary Delayed Release Tablet Formulation of Omeprazole OTC

Complex Injectable
(Co-development)

Complex injectable product equivalent to a well-known brand in the oncology field; Co-developed with CSPC Pharma

ViePax® XR
(Venlafaxine XR tablets)

Proprietary Extended Release Tablet formulation bioequivalent to capsule Effexor XR capsules

Profile
Dexcel In Numbers
History
Worldwide
Executive Team
Strategic Investments
Events
Business Ethics
Our History
1968
1989
1991
1992
1993
1996
1999
2002
2008
2010
2014
2015
1968
Dexcel Pharma founded in a small cabin with 9 workers
1968
Dexcel Pharma founded in a small cabin with 9 workers
1968
Dexcel Pharma founded in a small cabin with 9 workers
1989
Dexamol launch in Israel
1991
Supplying Doxylin® to Israel's national stockpile at time of crisis in record times
1992
Launch of first Dexcel Pharma product abroad
1993
To accommodate rapid growth, Dexcel Pharma moves to the new Or Akiva campus
1993
Dexcel Pharma subsidiary in Germany begins operations
1996
Dexcel Pharma subsidiary in the UK begins operations
1999
PerioChip® launch in the US market
2002
Omeprazole launch in the UK
2008
Omeprazole launch in the US
2008
40 years anniversary
2010
State-of-the-art manufacturing site becomes operational and receives FDA Approval
2010
State-of-the-art manufacturing site becomes operational and receives FDA Approval
2010
Or Akiva expansion continues
2010
Or Akiva expansion continues
2014
Opening of R&D center in Jerusalem
2014
Opening of R&D center in Jerusalem
2014
Opening of R&D center in Jerusalem
2015
Dexcel Pharma continues to grow and expand